These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31019022)

  • 21. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
    Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
    Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dedifferentiated Liposarcoma With Epithelioid/Epithelial Features.
    Makise N; Yoshida A; Komiyama M; Nakatani F; Yonemori K; Kawai A; Fukayama M; Hiraoka N
    Am J Surg Pathol; 2017 Nov; 41(11):1523-1531. PubMed ID: 28719466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.
    Zhou MY; Bui NQ; Charville GW; Ganjoo KN; Pan M
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
    Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
    Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Akiyama T; Iwata S; Sugaya J; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2022 May; 35(3):936-943. PubMed ID: 35292923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
    Somaiah N; Tap W
    Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
    Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
    Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Well-differentiated and dedifferentiated liposarcomas.
    Coindre JM; Pédeutour F; Aurias A
    Virchows Arch; 2010 Feb; 456(2):167-79. PubMed ID: 19688222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma.
    Jagosky MH; Anderson CJ; Symanowski JT; Steuerwald NM; Farhangfar CJ; Baldrige EA; Benbow JH; Livingston MB; Patt JC; Ahrens WA; Kneisl JS; Kim ES
    Cancer Med; 2023 Mar; 12(6):7029-7038. PubMed ID: 36464833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
    Seligson ND; Stets CW; Demoret BW; Awasthi A; Grosenbacher N; Shakya R; Hays JL; Chen JL
    Oncotarget; 2019 Oct; 10(55):5671-5679. PubMed ID: 31620242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of MDM2 Fluorescence In Situ Hybridization and Immunohistochemistry in Distinguishing Dedifferentiated Liposarcoma From Other High-grade Sarcomas.
    Song MJ; Cho KJ; Lee JS; Song JS
    Appl Immunohistochem Mol Morphol; 2017; 25(10):712-719. PubMed ID: 27028243
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Casadei L; Calore F; Braggio DA; Zewdu A; Deshmukh AA; Fadda P; Lopez G; Wabitsch M; Song C; Leight JL; Grignol VP; Lev D; Croce CM; Pollock RE
    Cancer Res; 2019 Oct; 79(19):4911-4922. PubMed ID: 31387924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features: a clinicopathological analysis of five cases].
    Si HP; Wang Z; Fan QH; Zhang YF; Yang DQ; Zhang ZH; Gong QX
    Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):282-287. PubMed ID: 30955263
    [No Abstract]   [Full Text] [Related]  

  • 34. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
    Creytens D; Van Gorp J; Speel EJ; Ferdinande L
    Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
    Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL
    Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment and characterization of a novel patient-derived cell line of dedifferentiated liposarcoma, NCC-DDLPS6-C1.
    Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Akiyama T; Nakagawa R; Kamio S; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2022 Jul; 35(4):1270-1278. PubMed ID: 35604485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
    Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
    Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen.
    Lee S; Park H; Ha SY; Paik KY; Lee SE; Kim JM; Park JB; Kwon CH; Joh JW; Choi YL; Kim SJ
    PLoS One; 2014; 9(8):e99452. PubMed ID: 25121597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
    Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL
    Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Characterization of a Rare Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation in a 24 Year Old.
    Olson N; Gularte-Mérida R; Selenica P; Da Cruz Paula A; Alemar B; Weigelt B; Lefferts J; Linos K
    Int J Surg Pathol; 2020 Jun; 28(4):454-463. PubMed ID: 31801397
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.